How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,465 results for

Melatonin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V

Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Melatonin (Schlafstörungen bei Kindern und Jugendlichen mit Autismus-Spektrum-Störung und/oder Smith-Magenis-Syndrom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A19-04 Melatonin (Insomnia in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-04 Version 1.0 Melatonin (Insomnia in children and adolescents with ASD and/or SMS) 11 April 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

2. Melatonin and agomelatine for preventing seasonal affective disorder. (Abstract)

Melatonin and agomelatine for preventing seasonal affective disorder. Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly starts in autumn or winter and remits in spring. The prevalence of SAD depends on latitude and ranges from 1.5% to 9%. The predictable seasonal aspect of SAD provides a promising opportunity for prevention in people who have a history of SAD. This is one of four reviews on the efficacy and safety of interventions (...) to prevent SAD; we focus on agomelatine and melatonin as preventive interventions.To assess the efficacy and safety of agomelatine and melatonin (in comparison with each other, placebo, second-generation antidepressants, light therapy, psychological therapy or lifestyle interventions) in preventing SAD and improving person-centred outcomes among adults with a history of SAD.We searched Ovid MEDLINE (1950- ), Embase (1974- ), PsycINFO (1967- ) and the Cochrane Central Register of Controlled Trials

2019 Cochrane

3. Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Last updated: February 22, 2019 Project Number: RC1073-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of melatonin for the treatment of insomnia in adults? What is the cost-effectiveness of melatonin for the treatment of insomnia in adults? What are the evidence-based guidelines regarding the use of melatonin for the treatment of insomnia in adults? Key Message Evidence of limited quality from four systematic reviews and two randomized controlled trials suggested modest favourable

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Melatonin: significant adverse effects

Melatonin: significant adverse effects Prescrire IN ENGLISH - Spotlight ''Melatonin: significant adverse effects'', 1 March 2019 {1} {1} {1} | | > > > Melatonin: significant adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Melatonin: significant adverse effects Melatonin is not a treatment of choice for sleep disorders: its efficacy (...) beyond that of a placebo is uncertain, and it carries a risk of neuropsychological, cutaneous, gastrointestinal and other adverse effects. Melatonin is a hormone secreted mainly by the brain, whose main function is to provide information to the body relating to the day/night cycle, and to promote sleep. In France, depending on the amount contained in a single (unit) dose, melatonin can be considered to have the status of either a drug or a food supplement. Irrespective of its dose and status

2019 Prescrire

5. Melatonin for the promotion of sleep in adults in the intensive care unit. Full Text available with Trip Pro

Melatonin for the promotion of sleep in adults in the intensive care unit. Patients in the intensive care unit (ICU) experience sleep deprivation caused by environmental disruption, such as high noise levels and 24-hour lighting, as well as increased patient care activities and invasive monitoring as part of their care. Sleep deprivation affects physical and psychological health, and patients perceive the quality of their sleep to be poor whilst in the ICU. Artificial lighting during night-time (...) hours in the ICU may contribute to reduced production of melatonin in critically ill patients. Melatonin is known to have a direct effect on the circadian rhythm, and it appears to reset a natural rhythm, thus promoting sleep.To assess whether the quantity and quality of sleep may be improved by administration of melatonin to adults in the intensive care unit. To assess whether melatonin given for sleep promotion improves both physical and psychological patient outcomes.We searched the Cochrane

2018 Cochrane

6. Melatonin (Slenyto) - insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old)

Melatonin (Slenyto) - insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) Slenyto | European Medicines Agency Search Search Menu Slenyto melatonin Table of contents Authorised This medicine is authorised for use in the European Union. Overview Slenyto is a medicine for treating insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) who have: autism spectrum disorder (ASD), a range of conditions that affects the patient’s social interactions (...) ; Smith-Magenis syndrome, a condition that can lead to learning difficulties. Slenyto is used after other measures such as keeping to a regular sleeping routine have not worked. The medicine contains the melatonin. Expand section Collapse section How is Slenyto used? Slenyto is available as tablets (1 and 5 mg). The normal dose is 2 mg taken 30 minutes to one hour before bedtime. The dose can be increased up to a maximum of 10 mg if the medicine is not working well enough. The doctor should review

2018 European Medicines Agency - EPARs

7. Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome

Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome 1 Published 9 September 2019 1 SMC2168 melatonin 1mg and 5mg prolonged-release tablets (Slenyto®) Flynn Pharma Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission melatonin prolonged-release (Slenyto ® ) is not recommended for use within NHSScotland. Indication under review: Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. Melatonin prolonged-release (Slenyto ® ), compared with placebo, increased total sleep time and sleep onset latency in children aged 2 to 17.5 years with sleep

2019 Scottish Medicines Consortium

8. Melatonin Increases Brown Adipose Tissue Volume and Activity in Melatonin Deficient Patients: a Proof-of-Concept Study. Full Text available with Trip Pro

Melatonin Increases Brown Adipose Tissue Volume and Activity in Melatonin Deficient Patients: a Proof-of-Concept Study. Melatonin, a pineal hormone synthesized at night, is critical for the synchronization of circadian and seasonal rhythms, being a key regulator of energy metabolism in many animal species. Although studies in humans are lacking, several reports, mainly on hibernating animals, demonstrate that melatonin supplementation and short photoperiod increase brown adipose tissue (BAT (...) ) mass. The present proof-of-concept study is the first, to our knowledge, to evaluate BAT in melatonin non-proficient patients (radiotherapy or surgical removal of pineal gland) before and after daily melatonin (3 mg) replacement for three months. All four studied patients presented increased BAT volume and activity measured by PET-MRI. We also found an improvement in total cholesterol and triglycerides blood levels, without significant effects on body weight, liver fat, HDL and LDL levels. Albeit

2019 Diabetes

9. Melatonin Is Superior to Amitriptyline for Headache Prevention Based on the Proportion of Patients Who Improved >50% in Headache Frequency

Melatonin Is Superior to Amitriptyline for Headache Prevention Based on the Proportion of Patients Who Improved >50% in Headache Frequency UTCAT3159, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Melatonin Is Superior to Amitriptyline for Headache Prevention Based on the Proportion of Patients Who Improved >50% in Headache Frequency Clinical Question In adults with migraine headaches, is melatonin superior than (...) amitriptyline in preventing the frequency and intensity of migraine headaches? Clinical Bottom Line For patients with migraine headaches, melatonin 3 mg is better than placebo for migraine prevention, more tolerable than amitriptyline, and as effective as amitriptyline 25 mg. Tolerability measures included the incidences of adverse events, including those that led to the premature withdrawal from the study as well as those that were life threatening. Best Evidence (you may view more info by clicking

2017 UTHSCSA Dental School CAT Library

10. The effects of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and inflammatory markers in type 2 diabetes mellitus patients with chronic periodontitis: a double-blind, placebo-controlled t (Abstract)

The effects of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and inflammatory markers in type 2 diabetes mellitus patients with chronic periodontitis: a double-blind, placebo-controlled t Diabetes mellitus (DM) and periodontitis are two common chronic diseases with bidirectional relationship. Oxidative stress plays a key role in the pathogenesis of these two diseases. The aim of this study was to investigate the effects (...) of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and inflammatory markers in type 2 DM patients with chronic periodontitis (CP).In this double-blind clinical trial study, 50 type 2 DM patients with CP were randomly allocated to the intervention and control groups. The intervention and control groups received either 6 mg melatonin or placebo (2 tablets) once a day. Serum levels of melatonin, tumor necrosis factor-alpha (TNF-α), interleukin

2018 Inflammopharmacology Controlled trial quality: uncertain

11. Long-Term Melatonin Therapy for Adolescents and Young Adults with Chronic Sleep Onset Insomnia and Late Melatonin Onset: Evaluation of Sleep Quality, Chronotype, and Lifestyle Factors Compared to Age-Related Randomly Selected Population Cohorts Full Text available with Trip Pro

Long-Term Melatonin Therapy for Adolescents and Young Adults with Chronic Sleep Onset Insomnia and Late Melatonin Onset: Evaluation of Sleep Quality, Chronotype, and Lifestyle Factors Compared to Age-Related Randomly Selected Population Cohorts The extent of continuance of melatonin therapy initiated in pre-pubertal children with chronic sleep onset insomnia (CSOI) was investigated in young adult life. Sleep timing, sleep quality, adverse events, reasons for cessation of therapy, and patient (...) of the survey, melatonin was still continued by 27.3% of the patients, with a mean treatment duration of 10.8 years. The overall average treatment duration was 7.1 years. Sleep quality of both discontinued and persistent melatonin users did not deviate from controls. Sleep timing and chronotype scores indicated evening type preference in all responders. Adverse events were scarce but the perceived timing of pubertal development suggested a tendency towards delayed puberty in former and current users

2018 Healthcare

12. Changes in Melatonin, Cortisol, and Body Temperature, and the Relationship Between Endogenous Melatonin Levels and Analgesia Consumption in Patients Undergoing Bariatric Surgery. (Abstract)

Changes in Melatonin, Cortisol, and Body Temperature, and the Relationship Between Endogenous Melatonin Levels and Analgesia Consumption in Patients Undergoing Bariatric Surgery. Melatonin has analgesic, anti-inflammatory, sedative, and anxiolytic properties. However, the relationship between endogenous melatonin levels and postoperative analgesic requirements has not been well elucidated in patients undergoing bariatric surgery. We studied endogenous melatonin levels, cortisol levels, body (...) temperatures, and the relationship between the level of endogenous melatonin and postoperative morphine consumption.The trial was conducted among 30 patients who were scheduled for laparoscopic bariatric surgery. Their ages were between 18 and 65 years and their BMIs were above 40 kg/m2. Secretion of melatonin, cortisol, and body temperature was monitored before the anesthetic induction, at 2 h intraoperatively, and at 2, 6, 10, (2:00 A.M.) and 24 h postoperatively. For each patient, morphine consumption

2018 Obesity Surgery

13. Melatonin inhibits apoptotic cell death induced by Vibrio vulnificus VvhA via melatonin receptor 2 coupling with NCF-1 Full Text available with Trip Pro

Melatonin inhibits apoptotic cell death induced by Vibrio vulnificus VvhA via melatonin receptor 2 coupling with NCF-1 Melatonin, an endogenous hormone molecule, has a variety of biological functions, but a functional role of melatonin in the infection of Gram-negative bacterium Vibrio vulnificus has yet to be described. In this study, we investigated the molecular mechanism of melatonin in the apoptosis of human intestinal epithelial (HCT116) cells induced by the hemolysin (VvhA) produced by V (...) . vulnificus. Melatonin (1 μM) significantly inhibited apoptosis induced by the recombinant protein (r) VvhA, which had been inhibited by the knockdown of MT2. The rVvhA recruited caveolin-1, NCF-1, and Rac1 into lipid rafts to facilitate the production of ROS responsible for the phosphorylation of PKC and JNK. Interestingly, melatonin recruited NCF-1 into non-lipid rafts to prevent ROS production via MT2 coupling with Gαq. Melatonin inhibited the JNK-mediated phosphorylation of c-Jun responsible for Bax

2018 Cell death & disease

14. Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials Full Text available with Trip Pro

Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials Atypical antipsychotics (AAPs) are increasingly used for the treatment of psychotic disorders but are known to be associated with metabolic abnormalities. This study is a systematic review and meta-analysis of randomized controlled trials (RCTs) studying the effectiveness of melatonin for the amelioration of AAP-induced (...) metabolic syndrome. The MEDLINE (accessed via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials, PsycINFO, LILACS, CINAHL, and OpenGrey databases were searched for RCTs without language restrictions. Inclusion criteria were randomized, double-blind clinical trials comparing melatonin or melatonin agonists with placebo for the amelioration of AAP-induced effects at any age with selected components of metabolic syndrome as outcome measures. Two reviewers independently

2018 Clinical Psychopharmacology and Neuroscience

15. Melatonin for women in pregnancy for neuroprotection of the fetus. (Abstract)

Melatonin for women in pregnancy for neuroprotection of the fetus. Melatonin is an antioxidant with anti-inflammatory and anti-apoptotic effects. Animal studies have supported a fetal neuroprotective role for melatonin when administered maternally. It is important to assess whether melatonin, given to the mother, can reduce the risk of neurosensory disabilities (including cerebral palsy) and death, associated with fetal brain injury, for the preterm or term compromised fetus.To assess (...) the effects of melatonin when used for neuroprotection of the fetus.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 January 2016).We planned to include randomised controlled trials and quasi-randomised controlled trials comparing melatonin given to women in pregnancy (regardless of the route, timing, dose and duration of administration) for fetal neuroprotection with placebo, no treatment, or with an alternative agent aimed at providing fetal neuroprotection. We also planned

2016 Cochrane

16. Melatonin as add-on treatment for epilepsy. (Abstract)

Melatonin as add-on treatment for epilepsy. This is an updated version of the original Cochrane review published in Issue 6, 2012.Epilepsy is one of the most common chronic neurological disorders. Despite the plethora of antiepileptic drugs (AEDs) currently available, 30% of people continue having seizures. This group of people requires a more aggressive treatment, since monotherapy, the first choice scheme, fails to control seizures. Nevertheless, polytherapy often results in a number (...) of unwanted effects, including neurological disturbances (somnolence, ataxia, dizziness), psychiatric and behavioural symptoms, and metabolic alteration (osteoporosis, inducement or inhibition of hepatic enzymes, etc.). The need for better tolerated AEDs is even more urgent in this group of people. Reports have suggested an antiepileptic role of melatonin with a good safety profile.To assess the efficacy and tolerability of melatonin as add-on treatment for epilepsy.For the latest update, we searched

2016 Cochrane

17. Melatonin as add-on treatment for epilepsy. (Abstract)

Melatonin as add-on treatment for epilepsy. This is an updated version of the original Cochrane review published in Issue 6, 2012.Epilepsy is one of the most common chronic neurological disorders. Despite the plethora of antiepileptic drugs (AEDs) currently available, 30% of people continue having seizures. This group of people requires a more aggressive treatment, since monotherapy, the first choice scheme, fails to control seizures. Nevertheless, polytherapy often results in a number (...) of unwanted effects, including neurological disturbances (somnolence, ataxia, dizziness), psychiatric and behavioural symptoms, and metabolic alteration (osteoporosis, inducement or inhibition of hepatic enzymes, etc.). The need for better tolerated AEDs is even more urgent in this group of people. Reports have suggested an antiepileptic role of melatonin with a good safety profile.To assess the efficacy and tolerability of melatonin as add-on treatment for epilepsy.For the latest update, we searched

2016 Cochrane

18. Melatonin for pre- and postoperative anxiety in adults. Full Text available with Trip Pro

Melatonin for pre- and postoperative anxiety in adults. Anxiety in relation to surgery is a well-known problem. Melatonin offers an atoxic alternative to benzodiazepines in ameliorating this condition in the pre- and postoperative period.To assess the effect of melatonin on pre- and postoperative anxiety in adults when comparing melatonin with placebo or when comparing melatonin with benzodiazepines.The following databases were searched on 19 April 2013: CENTRAL, MEDLINE, EMBASE, CINAHL and Web (...) of Science. For ongoing trials and protocols we searched clinicaltrials.gov, Current Controlled Trials and the World Health Organization (WHO) International Clinical Trials Registry Platform. We reran the search in October 2014. We will deal with any studies of interest when we update the review.Randomized, placebo-controlled or standard treatment-controlled, or both, studies that evaluated the effect of preoperatively administered melatonin on preoperative or postoperative anxiety. We included adult

2015 Cochrane

19. Melatonin and agomelatine for preventing seasonal affective disorder. (Abstract)

Melatonin and agomelatine for preventing seasonal affective disorder. Seasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly occurs during autumn or winter and remits in spring. The prevalence of SAD in the United States ranges from 1.5% to 9%, depending on latitude. The predictable seasonal aspect of SAD provides a promising opportunity for prevention. This is one of four reviews on the efficacy and safety of interventions to prevent (...) SAD; we focus on agomelatine and melatonin as preventive interventions.To assess the efficacy and safety of agomelatine and melatonin (in comparison with each other, placebo, second-generation antidepressants, light therapy, psychological therapy or lifestyle interventions) in preventing SAD and improving patient-centred outcomes among adults with a history of SAD.We conducted a search of the Specialised Register of the Cochrane Depression, Anxiety and Neurosis Review Group (CCDANCTR) to 11 August

2015 Cochrane

20. The Healthy Heart-Mind Trial: Randomized Controlled Trial of Melatonin for Prevention of Delirium (Abstract)

The Healthy Heart-Mind Trial: Randomized Controlled Trial of Melatonin for Prevention of Delirium Delirium is a serious medical condition with increased incidence in at-risk surgical populations. We sought to determine if melatonin use reduces the incidence of delirium in individuals undergoing major cardiac surgery.Randomized double-blind placebo-controlled clinical trial (two arms, 1:1 allocation, parallel design).The trial took place in two metropolitan hospitals (public tertiary and private (...) ) in Perth, Western Australia.We recruited 210 adults aged 50 years or older who were due to undergo coronary artery bypass grafting or valve replacement surgery.Participants were randomly assigned (1:1) to 7 days of treatment with melatonin 3 mg at night or matching placebo, starting 2 days before the surgery.The primary outcome of interest was incident delirium within 7 days of surgery as assessed via daily clinical assessment that included the Confusion Assessment Method. Secondary outcomes

2019 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>